Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866367 | 0.77 | DPP4 (0.56) | DPP4F2AOC3HTR2AADRA2A | |
| SCHEMBL14455234 | 0.77 | DPP4 (0.56) | DPP4F2AOC3HTR2AADRA2A | |
| SCHEMBL28763539 | 0.77 | DPP4 (0.56) | DPP4F2AOC3HTR2ATAAR1 | |
| SCHEMBL644767 | 0.74 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL2067094 | 0.74 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL851654 | 0.74 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL150159 | 0.74 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL239938 | 0.74 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL1878642 | 0.74 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL30802089 | 0.74 | DPP4 (0.52) | DPP4F2AOC3TAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696573-B1 | SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1209150-A1 | PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ADH1A, ADH1C, OXER1 | DPP4 686/4885F2 511/4885AOC3 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.